Europe PMC
open access
Repurposing FDA-approved drugs as multi-target neuroprotective agents for Alzheimer's disease via computational screening and experimental validation
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease#865253
- Intersection Of Capacity Law And Neurodegenerative Disease With A Focus On Alzheimer’s Medication#401534
- ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease#866669
- A Flexible-Horizon Clinical Decision Support Model for Dementia Early Detection and Risk Prediction in Secondary Care: A Responsible AI Approach#824311
- A (19)F MRI/NIR-FL Nanoprobe for "Turn-On" Imaging of β-Secretase (BACE1) Activity in Alzheimer's Disease.#388668
Record · ID 5503
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive